The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
about
Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemopreventionNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesSynergistic interaction between selective drugs in cell populations modelsContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsRestoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.Gold nanoparticles: From nanomedicine to nanosensing.EGFR soluble isoforms and their transcripts are expressed in meningiomas.Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Circular RNA participates in the carcinogenesis and the malignant behavior of cancer.Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.Role of erlotinib in the management of pancreatic cancer.Impact of EGFR and p53 expressions on survival and quality of life in locally advanced oral squamous cell carcinoma patients treated with chemoradiationErlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II studyA dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.Acute kidney injury after cardiovascular surgery: an overview.Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity.A mathematical model for the rational design of chimeric ligands in selective drug therapies.Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice.Profile of erlotinib and its potential in the treatment of advanced ovarian carcinomaThe evolving role of nuclear molecular imaging in cancer.Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
P2860
Q25255636-1D96F801-E051-4062-B093-8BEF6033A8ABQ26778150-A396A23F-6988-4669-9EC4-AF3BDDC82FA4Q26782809-7A9B019D-4046-4C7E-B6E8-126090E9005AQ27004292-335AE9E3-F999-4B09-B4C7-885E7EF61AD9Q28543382-0FE53546-DDB7-49C3-8394-D99A6252A4EDQ28547357-3BAD03A6-B08E-4B84-B113-37CD6BE314DAQ30438487-CAB85FCF-849C-4A5A-8176-74BAF0DC2928Q30447539-21D3D8E9-6B93-4381-888F-0CA789753043Q31062214-F0A61E76-C078-4DC8-B521-F06EB31370F8Q33243912-3EE647F2-D59E-4D8E-B2E7-A07F4017B7F5Q33292272-3AD5E838-6444-4D04-9BF8-BFBA08E04906Q33358967-2FAAA5D7-AEC9-421C-A954-244DF54C087AQ33543073-9CA98F8B-C306-4102-B04E-B44F2BAC3E49Q33677975-986AF86B-49FB-48E5-8386-CD0BFDE94B21Q33684453-34365CE5-378C-4A63-974D-DE04183633CFQ33739727-EC9CD09D-D35A-4014-AF73-CBF1800BB9D3Q33820267-9303F5AF-8B7E-454C-829F-B671E5DAD1B9Q33895537-CBE82897-1B0A-4564-B316-9EE581510DF9Q33983663-CCAD245E-E294-4C1C-A9F4-835465B8424DQ34126513-EAFEF9D6-4C14-405D-9EF5-8A03BAE9CB45Q34564071-85813B13-504D-49E6-A006-D520E4C06DBAQ34648886-C30EC702-24E7-4923-9265-F4C1956B4312Q34733314-13315925-C174-436A-95F8-567D32CF86CDQ34983846-D5E859C5-9421-462A-88B6-64094EB8C98DQ35017125-E591FFF3-75EA-437D-9845-E983AD77AD27Q35031831-C0AE732C-A2DD-42FA-A5EC-11C0C930C76CQ35624032-46C49399-C3A4-409D-A2FE-9C271D5DB20AQ35800058-1A2FDD5F-58B4-46C3-AE80-FDF48EF470FFQ35919264-676D4755-A1D9-402A-812D-FC57DC9BFD37Q36213310-EF3A9CCD-B380-42C9-B4AB-0F68463EBB12Q36216537-91EA9995-0B00-4BB5-B0CF-CD49ECFF741CQ36319721-46B889E4-3E64-4AF2-90CD-9071300D43E3Q36367023-9F9700F8-8632-43BF-9584-D11F67006694Q36514584-86A634D0-06C5-4D0F-AEF4-6133B9EE8B68Q36693739-432ECBE6-8403-4613-97E0-59A7FF7E082FQ36836865-751AC622-1005-4C8E-A624-1012F5E9E30CQ36880902-0FA1C833-2F8C-4DCA-BC80-0577C2B2C0D2Q37011086-C66C97E0-20C4-419D-98FE-6EC35B3A85B3Q37195581-50FAF231-504B-41E9-83DB-803050239AA9Q37233255-5D3992DD-5D76-4524-8475-5B6FA35A8D76
P2860
The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The epidermal growth factor re ...... tic target in human neoplasia.
@ast
The epidermal growth factor re ...... tic target in human neoplasia.
@en
The epidermal growth factor re ...... tic target in human neoplasia.
@nl
type
label
The epidermal growth factor re ...... tic target in human neoplasia.
@ast
The epidermal growth factor re ...... tic target in human neoplasia.
@en
The epidermal growth factor re ...... tic target in human neoplasia.
@nl
prefLabel
The epidermal growth factor re ...... tic target in human neoplasia.
@ast
The epidermal growth factor re ...... tic target in human neoplasia.
@en
The epidermal growth factor re ...... tic target in human neoplasia.
@nl
P1476
The epidermal growth factor re ...... tic target in human neoplasia.
@en
P2093
Arteaga CL
P304
P407
P433
P577
2001-09-01T00:00:00Z